Zurück zu den Rankings

iRhythm Technologies, Inc. (IRTC)

Fair bewertet
HealthcareMedical DevicesUnited States

Fundamental

43

Kurs

$111.79

Marktkapitalisierung

$3.75B

Teil 1 · Was das Unternehmen wert ist

Übersicht

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users

P/E: 17.7Score: 73Market cap: $63.93B

Its Preventice Solutions arm, acquired for $925 million, is the closest challenger to Zio in long-term continuous ECG patch monitoring in the United States.

P/E: —Score: 51Market cap: $12.14B

Baxter owns Bardy Diagnostics, whose Carnation ambulatory monitor patch is prescribed for the same arrhythmia work-ups that Zio is used for.

P/E: 15.7Score: 56Market cap: $30.20B

GE HealthCare supplies the traditional 24-to-48-hour Holter monitors that hospitals and clinics can choose instead of sending a patient home with a Zio patch.

Koninklijke Philips N.V. (Royal Philips)PHG

Through BioTelemetry, which it bought for $2.8 billion, Philips sells the wearable ECG patches and mobile cardiac telemetry services that compete directly with iRhythm's Zio for the same cardiologists and the same insurance reimbursement.

Medtronic plcMDT

Medtronic's LINQ family of insertable cardiac monitors targets the same patients under investigation for atrial fibrillation and unexplained fainting, competing for the diagnostic referral before a Zio is ever prescribed.

VitalConnect, Inc.Not tracked

This private US company sells the VitalPatch, a disposable ECG patch with AI arrhythmia detection sold to the same cardiology practices that buy Zio.

Bilanz & Liquidität

Umsatz

$825M

Letzte 12 Monate (bis 30.6.2026)

Nettogewinn

$-14M

Letzte 12 Monate (bis 30.6.2026)

Freier Cashflow

$35M

Gesamtes Eigenkapital

$153M

Gesamtverbindlichkeiten

$867M

Current Ratio

3.85

Zinsdeckungsgrad

1.89

Schulden/EBITDA

-

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Allgemeiner FallFair bewertet

Innerer Wert

$104.37

Aktueller Kurs

$111.79

Sicherheitsmarge

-7.1%

Innerer-Wert-Spanne

$67.84 - $140.89

Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.

Bewertungsmethoden

Kursziel der Analysten:$176.14
Diskontierter Cashflow (DCF):$14.64
Gewinnmultiplikator (P/E):Nicht genügend Daten zur Berechnung
Graham-Wachstumsformel:Nicht genügend Daten zur Berechnung
Ertragskraftwert (EPV):Nicht genügend Daten zur Berechnung
Gerechtfertigtes P/B:Nicht genügend Daten zur Berechnung
Dividendendiskontierung (Gordon):Nicht genügend Daten zur Berechnung
P/FFO, Funds from Operations:Nicht genügend Daten zur Berechnung
Gewinn im Zyklusmittel:Nicht genügend Daten zur Berechnung
Umsatzmultiplikator:$98.85
Analystenkonsens:Starker Kauf (20B / 1H / 0S)
Letzte Gewinnüberraschung:+12988.89%

Bewertungskennzahlen

P/E-Verhältnis

-

ROE

-29.2%

P/B-Verhältnis

20.14

P/FCF

96.12

Bruttomarge

71.5%

ROIC

-2.2%

Rentabilitäts-Radar

Wertschöpfung (Wettbewerbsvorteil)

ROIC

-2.2%

WACC

10.5%

ROIC − WACC

-12.7 pp

Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.

Fundamentalanalyse-Kriterien

Bestanden (12)

  • EPS shows upward trend
  • Price CAGR 14.06%
  • Gross Margin 71.5%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Low reliance on intangibles
  • Revenue Growth 5Y 23.0%
  • Analyst Consensus 95% Buy
  • Earnings Surprise avg 3463.2%
  • Net Margin Trend -1.7% vs -14.1%
  • Piotroski F-Score 6/9

Nicht bestanden (10)

  • ROIC -2.2%
  • P/FCF 96.12
  • P/B Ratio 20.14
  • Debt/Equity ratio
  • Operating Margin -3.0%
  • CapEx intensity
  • Return on Tangible Assets
  • DCF valuation (Overvalued)
  • ROE -9.0%
  • Share Dilution 2.7%

Nicht verfügbar (5)

  • Dividend Payout NaN%
  • Debt/EBITDA
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-Score

6/9

Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit

score
criteria

Gewinnqualität

-

Niedrige Qualität: Rechnungslegung prüfen

Aktienverwässerung

2.7%

Neue Aktien werden ausgegeben, Eigentum wird verwässert

Institutionelle Beteiligungen

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Quentin S. BlackfordPresident, CEO & Director46
Mr. Daniel G. WilsonCFO & Principal Financial Officer43
Dr. Minang P. Turakhia M.D., M.S.Chief Medical & Scientific Officer and Executive VP of Advanced Technologies51
Mr. Patrick Michael Murphy J.D.Chief Business & Legal Officer46
Mr. Chad M. PattersonChief Commercial and Product Officer43
Mr. Mervin SmithExecutive Vice President of Business Operations50
Mr. Marc RosenbaumSenior VP of Finance & Chief Accounting Officer52
Mr. Brian LawrenceExecutive VP & CTO55
Ms. Lisa PecoraSenior Vice President of Finance & Investor Relations-
Mr. Sean Clinton FreemanExecutive Vice President of Strategy & Corporate Development49

Prüfungsrisiko

9

Vorstandsrisiko

5

Vergütungsrisiko

3

Aktionärsrechterisiko

7

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Dokumente

  • Jahresbericht (10-K)

    Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

    Eingereicht am 2026-02-19

    Dokument ansehen
  • Quartalsbericht (10-Q)

    Ein Update zur finanziellen Entwicklung der letzten drei Monate.

    Eingereicht am 2026-08-06

    Dokument ansehen
  • Ad-hoc-Meldung (8-K)

    Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

    Eingereicht am 2026-09-22

    Dokument ansehen

via SEC EDGAR

Ertragshistorie

via SEC EDGAR

Latest News

Recent headlines for IRTC, sourced from Markets Gazette.

  • 3d agoPOSITIVE
    JP Morgan forecasts a 20x revenue increase for this AI stock

    JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.

  • 6/16/2026NEGATIVE
    iRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data

    iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.

via Markets Gazette